You are here

Mutation Enriched Targeted Re Sequencing

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42CA180389-02A1
Agency Tracking Number: R42CA180389
Amount: $1,490,022.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: 103
Solicitation Number: PA14-072
Timeline
Solicitation Year: 2014
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-01-01
Award End Date (Contract End Date): 2017-12-31
Small Business Information
12325 EMMET ST, Omaha, NE, 68164-4268
DUNS: 969419258
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 GRANT WU
 (402) 452-5400
 gwu@transgenomic.com
Business Contact
 PAUL KINNON
Phone: (301) 926-3549
Email: pkinnon@transgenomic.com
Research Institution
 DANA-FARBER CANCER INST
 450 Brookline Avenue
BOSTON, MA, 02215-5450
 Domestic nonprofit research organization
Abstract
DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used technologies such as sequencing are not sensitive enough to detect these mutations when they are at very low percentages compared to normal DNA Likewise the next generation sequencing technologies NGS are promising technology advances that can effectively detect prevalent somatic mutations in targeted gene panels however due to the limited quantity of DNA in most patient samples and the abundance of normal DNA when analyzing blood NGS andapos loses steamandapos and its integration with clinical practice is problematic For mutations at an abundance of or below NGS generates false positives `noiseandapos independent of sequencing depth yet these are often the clinically relevant mutations causing resistance to drug treatments Commercial sample preparation kits for targeted re sequencing of cancer gene panels have emerged however they are uniformly unable to detect mutations below a abundance level Thus while targeted re sequencing provides an opportunity for integration of NGS with clinical oncology the technology is ineffective in detecting DNA mutations in circulating DNA urine or heterogeneous cancers We intend to use COLD PCR a recently developed method that enriches unknown mutation containing sequences over wild type normal alleles during PCR amplification In previous work we showed COLD PCR NGS based sequencing for mutations down to abundance However COLD PCR was only applicable with a single amplicon per reaction limiting its efficient combination with NGS This STTR proposes a simple and powerful modification that enables COLD PCR to be applied to hundreds or thousands of DNA targets in a single reaction thus enabling mutation enrichment in disease specific gene panels prior to NGS The new approach temperature tolerant COLD PCR TT COLD PCR converts the rare mutations to high abundance mutations overcoming the `noiseandapos and avoiding the costly need for repeated sequence reads during NGS In Phase I we obtained proof of principle for TT COLD PCR In Phase II TT COLD PCR will be developed into kits for cancer specific gene panels to magnify rare mutations in multiple DNA targets thus enabling expanded application of targeted re sequencing for heterogeneous cancers or circulating DNA This project meets one of the aims of the NCI to support the development of new methods of diagnosis for the detection discovery and validation of biomarkers for cancer detection diagnosis and prognosis PUBLIC HEALTH RELEVANCE Screening of patientsandapos tumors for genetic alterations over many genes in a minimally invasive rapid and cost effective manner is a significant challenge that must be fulfilled in order to realize the promise of individualized cancer treatment Although major advances have been made there is still a significant gap in technology that prevents molecular profiling from repeated blood collections `liquid biopsiesandapos This STTR project provides an answer to this challenge by employing a new technology TT COLD PCR in combination with Next Generation Sequencing This novel approach overcomes technical limitations and enables reliable mutation screening in multiple genes simultaneously in bodily fluids or surgical cancer samples from individual patients In view of the fundamental role of mutations in causing cancer and modulating tumor response to drug treatment this project has significant implications for public health

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government